1-3 of 3
Udo Siebolts
Close
Sort by
Journal Articles

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Nadja Jaekel, Susann Schulze, MD, Udo Siebolts, MD, Anja Haak, PhD, Nikolaos Pazaitis, MD, Michael Cross, PhD, Dietger Niederwieser, MD, Mathias Hänel, MD, Georg Maschmeyer, MD, Maxi Wass, MD, Lukas Heukamp, MB PhD, Roopika Menon, Miriam Bertrand, Claudia Wickenhauser, MD, Oana Brosteanu, PhD, Haifa Kathrin Al-Ali, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1420.
https://doi.org/10.1182/blood-2019-127865
Published: 2019
Journal Articles

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Karolin Hubert, Mrs, Thoralf Lange, MD, Udo Siebolts, Claudia Wichenhauser, MD, Gopalakrishna Prashanth, MD MRCS, Dietger Niederwieser, MD, Astrid Monecke, MD
Journal: Blood
Blood (2014) 124 (21): 1836.
https://doi.org/10.1182/blood.V124.21.1836.1836
Published: 2014
Journal Articles

Establishment of a Highly Sensitive Allele Specific Wild Type Blocker Polymerase Chain Reaction Followed by Pyrosequencing for Detection of the p.D816V Point Mutation.

Udo Siebolts, MD, MSc, Haifa Kathrin Al-Ali, MD, Dietger Niederwieser, MD, Claudia Wickenhauser, MD
Journal: Blood
Blood (2009) 114 (22): 4975.
https://doi.org/10.1182/blood.V114.22.4975.4975
Published: 2009